Age Group
	Patients With Newly Diagnosed HIV-⁠1		Patients Initiated With PrEP
	10-17 y	18-64 y	10-17 y	18-64 y
Total No. of patients	220	18 154	175	34 123
Age (y), mean (SD)	14.7 (2.2)	38.8 (12.8)	15.7 (1.4)	34.7 (11.0)
Gender, n (%)
Male	132 (60.0)	11 578 (63.8)	53 (30.3)	31 037 (91.0)
Female	88 (40.0)	6576 (36.2)	122 (69.7)	3086 (9.0)
Region, n (%)
Northeast	49 (22.3)	4621 (25.5)	48 (27.4)	7476 (21.9)
North Central	29 (13.2)	2279 (12.6)	50 (28.6)	5398 (15.8)
South	124 (56.4)	9281 (51.1)	59 (33.7)	13 995 (41.0)
West	17 (7.7)	1814 (10.0)	16 (9.1)	7001 (20.5)
Unknown	1 (0.5)	159 (0.9)	2 (1.1)	253 (0.7)
Commercial plan type, n (%)
HMO	26 (11.8)	1790 (9.9)	28 (16.0)	4770 (14.0)
PPO	104 (47.3)	9019 (49.7)	80 (45.7)	16 363 (48.0)
POS	27 (12.3)	2289 (12.6)	0 (0.0)	3996 (11.7)
CDHP/HDHP	53 (24.1)	3765 (20.7)	39 (22.3)	7235 (21.2)
Othersa	2 (0.9)	759 (4.2)	0 (0.0)	1011 (3.0)
Unknown	8 (3.6)	532 (2.9)	1 (0.6)	748 (2.2)
Year of diagnosis (newly diagnosed HIV-1) or treatment index date (initiated with PrEP), n (%)
2016	69 (31.4)	4315 (23.8)	25 (14.3)	5504 (16.1)
2017	43 (19.5)	3876 (21.4)	31 (17.7)	6392 (18.7)
2018	42 (19.1)	3926 (21.6)	40 (22.9)	8123 (23.8)
2019	36 (16.4)	3022 (16.6)	44 (25.1)	7108 (20.8)
2020	23 (10.5)	2441 (13.4)	32 (18.3)	5457 (16.0)
2021b	7 (3.2)	574 (3.2)	3 (1.7)	1539 (4.5)
QCI, mean (SD)	0.2 (0.5)	0.4 (1.1)	0.2 (0.4)	0.2 (0.5)
Comorbid condition, n (%)
Prediabetes	1 (0.5)	187 (1.0)	2 (1.1)	310 (0.9)
Type 2 diabetes	2 (0.9)	1671 (9.2)	0 (0.0)	1454 (4.3)
Cardiovascular disease	1 (0.5)	568 (3.1)	0 (0.0)	302 (0.9)
Hypertension	4 (1.8)	3876 (21.4)	2 (1.1)	4735 (13.9)
Hyperlipidemia	12 (5.5)	3266 (18.0)	4 (2.3)	4920 (14.4)
Obesity	7 (3.2)	2213 (12.2)	11 (6.3)	3199 (9.4)
Nonalcoholic steatohepatitis	0 (0.0)	375 (2.1)	0 (0.0)	441 (1.3)
Cancer	3 (1.4)	635 (3.5)	1 (0.6)	311 (0.9)
Lipodystrophy	0 (0.0)	3 (0.0)	0 (0.0)	5 (0.0)
Opportunistic infections	0 (0.0)	513 (2.8)	0 (0.0)	1042 (3.1)
Substance abuse disorders	6 (2.7)	1839 (10.1)	31 (17.7)	2374 (7.0)
Depression/anxiety	32 (14.5)	2920 (16.1)	79 (45.1)	8379 (24.6)
Concomitant medication use, n (%)
Diabetes therapies	3 (1.4)	1154 (6.4)	3 (1.7)	1335 (3.9)
Psychiatric/neurologic therapies	30 (13.6)	2961 (16.3)	64 (36.6)	7641 (22.4)
Steroids	4 (1.8)	738 (4.1)	0 (0.0)	555 (1.6)
Hormone therapy/contraception	0 (0.0)	581 (3.2)	2 (1.1)	1345 (3.9)
Appetite stimulants/suppressants	14 (6.4)	704 (3.9)	35 (20.0)	2421 (7.1)
Antihypertensives	5 (2.3)	2345 (12.9)	12 (6.9)	3624 (10.6)
Statins	1 (0.5)	1548 (8.5)	1 (0.6)	2478 (7.3)